Kun Wang

Kun Wang

Auto-generated profile, based on publicly available information

Kun Wang

Cancer Data Science Laboratory (CDSL), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
MBMahashweta Basu
Mahashweta Basu
KWKun Wang
Kun Wang
EREytan Ruppin
Eytan Ruppin
SHSridhar Hannenhalli
Sridhar Hannenhalli
Machine learning tool TEEBoT predicts an individual’s tissue-specific gene expression from his/her blood transcriptome.

12 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SZSara Zahraeifard
Sara Zahraeifard
ZXZhiguang Xiao
Zhiguang Xiao
JSJae Young So
Jae Young So
AAAbdul Ahad
Abdul Ahad
SMSelina Montoya
Selina Montoya
YLYang Li
Yang Li
Low response rate, treatment relapse, and resistance remain key challenges for cancer treatment with immune checkpoint blockade (ICB). Here we report that loss of specific tumor suppressors (TS) induces an inflammatory response and promotes an immune suppressive tumor microenvironment. Importantly, low expression of these TSs is associated with a higher expression of immune checkpoint inhibitory mediators. Here we identify, by using in vivo CRISPR/Cas9 based loss-of-function screening, that NF1, TSC1, and TGF-β RII as TSs regulating immune composition. Loss of each of these three TSs leads to alterations in chromatin accessibility and enhances IL6-JAK3-STAT3/6 inflammatory pathways. This results in an immune suppressive landscape, characterized by increased numbers of LAG3+ CD8 and CD4 T cells. ICB targeting LAG3 and PD-L1 simultaneously inhibits metastatic progression in preclinical triple negative breast cancer (TNBC) mouse models of NF1-, TSC1- or TGF-β RII- deficient tumors. Our study thus reveals a role of TSs in regulating metastasis via non-cell-autonomous modulation of the immune compartment and provides proof-of-principle for ICB targeting LAG3 for patients with NF1-, TSC1- or TGF-β RII-inactivated cancers.

7 March 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
VBVahid Bahrambeigi
Vahid Bahrambeigi
JLJaewon Lee
Jaewon Lee
VBVittorio Branchi
Vittorio Branchi
KRKimal I. Rajapakshe
Kimal I. Rajapakshe
ZXZhichao Xu
Zhichao Xu
PGPaola A. Guerrero
Paola A. Guerrero
Longitudinal monitoring of patients with advanced cancers is crucial to evaluate both disease burden and treatment response. Current liquid biopsy approaches mostly rely on the detection of DNA-based biomarkers. However, plasma RNA analysis can unleash tremendous opportunities for tumor state interrogation and molecular subtyping. Through the application of deep learning algorithms to the deconvolved transcriptomes of RNA within plasma extracellular vesicles (evRNA), we successfully predicted consensus molecular subtypes in patients with metastatic colorectal cancer. Analysis of plasma evRNA also enabled monitoring of changes in transcriptomic subtype under treatment selection pressure and identification of molecular pathways associated with recurrence. This approach also revealed expressed gene fusions and neoepitopes from evRNA. These results demonstrate the feasibility of using transcriptomic-based liquid biopsy platforms for precision oncology approaches, spanning from the longitudinal monitoring of tumor subtype changes to the identification of expressed fusions and neoantigens as cancer-specific therapeutic targets, sans the need for tissue-based sampling. Significance: The development of an approach to interrogate molecular subtypes, cancer-associated pathways, and differentially expressed genes through RNA sequencing of plasma extracellular vesicles lays the foundation for liquid biopsy–based longitudinal monitoring of patient tumor transcriptomes.

6 December 2024 in Science Advances
Verified
Journal Article
Open access
NSNeel Sanghvi
Neel Sanghvi
CCCamilo Calvo-Alcañiz
Camilo Calvo-Alcañiz
PRPadma S. Rajagopal
Padma S. Rajagopal
SSStefano Scalera
Stefano Scalera
VCValeria Canu
Valeria Canu
NNNishanth Ulhas Nair
Nishanth Ulhas Nair
Metastasis is a leading cause of cancer-related deaths, yet understanding how metastatic tumors adapt from their origin to their target tissues remains a fundamental challenge. To address this, we assessed whether primary and metastatic tumors more closely resemble their tissues of origin or target tissues in terms of gene expression. We analyzed expression profiles from multiple cancer types and normal tissues, including single-cell and bulk RNA sequencing data from both paired and unpaired patient cohorts. Primary tumors were overall more transcriptomically similar to their tissues of origin, while metastases shifted toward their target tissues. However, pathway-level analysis highlighted critical metabolic and immune transcriptomic changes toward target tissues during metastasis in both primary and metastatic tumors. In addition, primary tumors exhibited higher activity in cancer hallmarks such as “Activating Invasion and Metastasis” when compared to metastases. This comprehensive analysis provides a transcriptome-wide view of the processes through which cancer tumors adapt to their metastatic environments before and after metastasis.

1 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBinbin Wang
Binbin Wang
RSRobert Saddawi-Konefka
Robert Saddawi-Konefka
LCLauren M. Clubb
Lauren M. Clubb
STShiqi Tang
Shiqi Tang
DWDi Wu
Di Wu
EREytan Ruppin
Eytan Ruppin
Immune checkpoint blockade (ICB) has improved outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but predictive biomarkers remain limited. Here, we use a time-resolved, multi-omic approach in a murine HNSCC model to characterize peripheral immune responses to ICB. Single-cell transcriptomics and T/B cell receptor analyses reveal early on-treatment expansion of effector memory T and B cell repertoires in responders, preceding tumor regression. These dynamic immune features inform a composite transcriptional signature that accurately predicts ICB response in independent human HNSCC cohorts. LiBIO outperforms existing biomarkers and generalizes to melanoma, non-small cell lung cancer, and breast cancer without retraining. These findings suggest that early treatment-induced changes in circulating immune repertoires reflect the host’s capacity to mount an effective antitumor response. This work provides a framework for leveraging transient peripheral immune dynamics to develop non-invasive, high-fidelity biomarkers for response to immunotherapy across cancer types.

1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
YCYingying Cao
Yingying Cao
TCTiangen Chang
Tiangen Chang
FSFiorella Schischlik
Fiorella Schischlik
KWKun Wang
Kun Wang
SSSanju Sinha
Sanju Sinha
EREytan Ruppin
Eytan Ruppin
In this study, we explore the possibility of inferring characteristics of the tumor immune microenvironment from the blood. Specifically, we investigate two datasets of patients with head and neck squamous cell carcinoma with matched single-cell RNA sequencing (scRNA-seq) from peripheral blood mononuclear cells (PBMCs) and tumor tissues. Our analysis shows that the immune cell fractions and gene expression profiles of various immune cells within the tumor microenvironment can be inferred from the matched PBMC scRNA-seq data. We find that the established exhausted T-cell signature can be predicted from the blood and serve as a valuable prognostic blood biomarker of immunotherapy response. Additionally, our study reveals that the inferred ratio between tumor memory B- and regulatory T-cell fractions is predictive of immunotherapy response and is superior to the well-established cytolytic and exhausted T-cell signatures. These results highlight the promising potential of PBMC scRNA-seq in cancer immunotherapy and warrant, and will hopefully facilitate, further investigations on a larger scale. The code for predicting tumor immune microenvironment from PBMC scRNA-seq, TIMEP, is provided, offering other researchers the opportunity to investigate its prospective applications in various other indications. Significance: Our work offers a new and promising paradigm in liquid biopsies to unlock the power of blood single-cell transcriptomics in cancer immunotherapy.